New blood test aims to spot prostate cancer cells earlier
NCT ID NCT01402154
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The results could help doctors decide on the best treatment approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EPISPOT blood test
What this could lead to
If successful, this could lead to a more accurate blood test to detect prostate cancer cells early, helping doctors choose the best treatment.
What could go wrong
This is a completed study comparing two detection methods, not a treatment trial. The test may not prove better than existing methods or may not change patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Montpellier - Hôpital Lapeyronie
Montpellier, 34295, France
-
CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH
Montpellier, 34295, France
-
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, Gard, 30029, France
-
Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque
Montpellier, 34298, France
-
Clinique Beau Soleil
Montpellier, 34070, France